Subsequent Review Sample Clauses

Subsequent Review. A) When the Commission approves a salary rate above the minimum pursuant to 14.2.1.1 A) 1. above, they will publicize in the Government of Saskatchewan's Career Centre the rate at which it has given such approval and an outline of the qualifications of the person appointed. B) Any employee working in the same occupation and classification level, with the same duties and responsibilities that is being paid at a rate lower in the range may challenge the appointment. The employee must possess the qualifications equivalent to those of the employee appointed higher in the salary range and within thirty (30) calendar days of such publication, request that the Commission review their qualifications and salary. If, as a result of review, a salary adjustment is considered to be warranted, the Commission shall so authorize. C) When market reasons warrant a higher salary rate the Commission shall review the qualifications of employees in the same occupation and classification level, with the same duties and responsibilities as the person appointed, and, where necessary, adjust their salary.

Subsequent Review. A) When the Commission approves a salary rate above the minimum pursuant to 14.2.1.1 A) 1. above, they will publicize in the Government of Saskatchewan's Career Centre the rate at which it has given such approval and an outline of the qualifications of the person appointed. B) Any employee working in the same occupation and classification level, with the same duties and responsibilities that is being paid at a rate lower in the range may challenge the appointment. The employee must possess the qualifications equivalent to those of the employee appointed higher in the salary range and within thirty

Subsequent Review. 7.1 Medtronic shall be entitled to discontinue any Earned Royalty payments under Article 4.2 of this Agreement in respect to any country or non-US foreign territory where a Licensed Patent exists immediately upon the occurrence of: 7.1.1 in any reexamination, reissue or court proceeding of the Licensed Patent applicable to that country or foreign territory, entry of a judgment, order, decree or decision to the effect that: (A) all of the claims of such Licensed Patent are invalid, or; (B) the use of human platelet releasate (or the sale or offering for sale of products substantially equivalent to the Royalty-Bearing Products) to facilitate healing of human wounds or human tissue infringes none of the valid and enforceable claims of such Licensed Patent, or 7.1.2 Licensor expressly and in writing disclaims or abandons any independent claim in any Licensed Patent applicable to that country or foreign territory, or 7.1.3 claims in any Licensed Patent applicable to that country or foreign territory are disallowed or so substantially narrowed in any reexamination proceeding, such that the Royalty-Bearing Products would be rendered non-infringing. 7.1.4 In the event Licensor obtains reversal of any adverse determination in Article 7.1.1 or 7.1.3 hereof that enabled Medtronic to discontinue any Earned Royalty payments, then Medtronic shall resume Earned Royalty payments affected thereby, and pay Licensor any Earned Royalties which accrued between suspension and resumption of Earned Royalty payments. Under no circumstances shall Medtronic's obligation to Licensor to make Earned Royalty payments extend beyond the term of this Agreement set forth in Article 4.2.3.

Subsequent Review. [No longer used]

Subsequent Review. Whether or not Purchaser shall have furnished to Seller any objection to matters disclosed on the Title Commitment or Survey pursuant to the foregoing provisions of this Agreement, Purchaser may, at or prior to Closing, notify Seller in writing of any objections to title or matters of survey first arising or raised by the Title Company or the surveyor between the effective date of the Title Commitment or the Survey (as applicable), and the Closing Date (“Gap Period Objections”), so long as such title or survey matter is not attributable to Purchaser or Purchaser’s inspections. Each party shall notify the other of any Gap Period Objections by written notice within two (2) business days of learning of the Gap Period Objections. Purchaser reserves the right to date down the Title Commitment at any time (at its expense) in order to verify that no Gap Period Objections have arisen, provided that the additional cost or expense of any such date down shall be borne by Purchaser. Subject to Seller’s obligation to cure Unpermitted Title Exceptions which shall also apply to any Gap Period Objections (but only to the extent the same are not attributable to Purchaser), Seller shall have until the earlier of two (2) business days after receipt of Purchaser’s notice of any Gap Period Objection, or the Closing Date, to give Purchaser notice that (i) Seller will remove or cure such Gap Period Objection; or (ii) Seller elects not to cause such Gap Period Objection to be removed or cured. If Seller agrees to cure the Gap Period Objection, then Seller shall do so prior to the Closing Date. If such objection is not so cured or satisfied, and such Gap Period Objection 400 ▇. ▇▇▇▇▇▇▇▇▇ PSA 10 is not attributable to Purchaser, then Purchaser may by written notice to Seller either (a) terminate this Agreement, in which case the ▇▇▇▇▇▇▇ Money shall be returned to Purchaser by Escrow Agent, and the parties shall have no further rights or obligations hereunder, except for those provided in Paragraph 8.2 if any such Gap Period Objection is the result of any breach of this Agreement by Seller, and except for those which expressly survive any such termination, or (b) waive its objections hereunder and proceed with the transaction pursuant to the remaining terms and conditions of this Agreement.